Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

Available source content was suppressed because validation identified a conflict.

Innovator Semaglutide

Core clinician-reference fields are available or not applicable.

Participants received generic semaglutide for 24 weeks in a step-wise dose escalation.

Generic Semaglutide

Participants were randomized 1:1 to receive either generic semaglutide (Alkem laboratories Ltd.) or innovator Inj. semaglutide (Novo Nordisk) for 24 weeks in step-wise dose escalation from 0.25 mg/week to 2 mg/week.

Participants received innovator semaglutide for 24 weeks in a step-wise dose escalation.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Generic semaglutide is as effective as innovator version for diabetes control

Reference semaglutide injection (comparator)

Patients received once-weekly semaglutide injection for 24 weeks.

Once-weekly semaglutide injection (test)

In this multicentre, randomised study, 314 patients aged 18–65 years with HbA1c 7.0–10.5 % were randomised 1:1 to once-weekly semaglutide injection (test) or reference semaglutide for 24 weeks.

Patients received reference semaglutide injection for 24 weeks.

Novel Semaglutide Injection Shows Non-Inferior Glycemic Control

Placebo

Participants receiving semaglutide 2.4 mg

Semaglutide 2.4 mg

Participants receiving semaglutide 2.4 mg (n = 129) compared with those receiving placebo (n = 64) had greater reductions from baseline in fasting serum insulin (−33.6% vs. −10.1%; P = 0.0012)...

Participants receiving placebo (n = 64) had greater reductions from baseline in fasting serum insulin (−10.1% vs. −33.6%; P = 0.0012)...

Authoritative quality diagnostic: age group conflict.

Semaglutide × Fasting Plasma Glucose (FPG)

Available supporting studies

Generic semaglutide is as effective as innovator version for diabetes control

Novel Semaglutide Injection Shows Non-Inferior Glycemic Control

Semaglutide improves insulin sensitivity in adolescents with obesity